To discuss examples of drug delivery translation
To discuss pathways of drug delivery development: devices to drugs
To discuss optimal pathways of drug delivery for specific tumours
Introduction by Professor David Walker
University of Nottingham & Children’s Brain Tumour Drug Delivery Consortium
13:00 – 13:05 British Summer Time
Our high profile national and international speakers include:
Associate Professor Sabine Mueller, University of Zurich
Title of talk: Convection enhanced delivery drug strategies for pediatric diffuse intrinsic pontine gliomas (DIPG)
Chair: Prof David Walker
13:05 – 13:25 British Summer Time
Sabine Mueller earned her medical degree and Ph.D. in biochemistry and molecular biology from the University of Hamburg, Germany. After a pediatric residency at Massachusetts General Hospital in Boston, she completed a fellowship in child neurology as well as in pediatric neuro-oncology at the University of California, San Francisco (UCSF). She is an Associate Professor in the Department of Neurology, Neurosurgery and Pediatric at UCSF. She is the Project Leader of the Pacific Pediatric Neuro-Oncology consortium (PNOC), a 22-member clinical trial consortium dedicated to develop innovative trials for children with brain tumors with international presence. Since 2019 she directs the Diffuse Midline Center at the University Children’s Hospital of Zürich, Switzerland. She has led many clinical trials for children with brain tumors including trials assessing convection enhanced delivery strategies for children with diffuse midline gliomas.
Professor Oren Scherman, University of Cambridge
Title of talk: Overcoming the Blood-Brain Barrier: Post-resection drug delivery to Glioblastoma Multiforme using Supramolecular Hydrogels
Chair: Dr Ruman Rahman
13:25 – 13:45 British Summer Time
Oren Scherman is a native of Norman, Oklahoma (USA), he graduated from Cornell University in Ithaca, New York, with a BA in Chemistry in 1999. He then moved to Pasadena, California, where he completed a PhD in 2004 in olefin metathesis and controlled polymerisation, under the supervision of Professor Robert H. Grubbs at the California Institute of Technology (Caltech). After finishing his PhD, Oren moved to the Netherlands to work on supramolecular polymers with Professors E.W. Meijer and Rint P. Sijbesma at the Eindhoven University of Technology. In 2006, he moved to the University of Cambridge to take up an academic appointment as a University Lecturer and Next Generation Fellow in the Melville Laboratory for Polymer Synthesis in the Department of Chemistry. In 2012, he was promoted to Reader in Supramolecular and Polymer Chemistry and in March 2013, he was appointed as the Director of the Melville Laboratory; Oren was promoted to Full Professor in 2015.
During the 2013-2014 academic year, Oren was on sabbatical at Tsinghua University as the Xuetang Visiting Professor in Chemistry. His research focuses on dynamic supramolecular self-assembly at interfaces though the application of macrocyclic host-guest chemistry using cucurbit[n]urils in the development of novel supramolecular systems. The Scherman group exploits control over these molecular level interactions to design and fabricate soft materials with integrated function.
Current research topics include drug-delivery systems, sensing and catalysis. Of specific interest is the design of functional soft materials including biocompatible hydrogels for drug-delivery applications, tough supramolecular polymer networks and bioinspired supramolecular fibres.
Dr Michael Canney, CarThera
Title of talk: Ultrasound mediated blood-brain-barrier opening: from concept to high grade glioma clinical trials
Chair: Dr Ruman Rahman
13:45 – 14:05 British Summer Time
Michael Sean Canney received the B.S. degree in mechanical engineering in 2004 from Boston University and the Ph.D. degree in Bioengineering in 2009 from the University of Washington in Seattle. His doctoral research involved characterization of nonlinear high intensity focused ultrasound fields (HIFU) and the use of shock waves to induce millisecond boiling in tissue. He subsequently conducted post-doctoral research at LabTAU/INSERM U1032 in Lyon, France.
He is currently the Scientific Director of CarThera, a startup company that is developing ultrasound-based medical devices for treating brain disorders. The company is a spin-off from AP-HP, Greater Paris University Hospitals, the largest hospital group in Europe, and Sorbonne University. Since 2010, CarThera has been leveraging the inventions of Professor Alexandre Carpentier, a neurosurgeon at AP-HP. CarThera developed the SonoCloud®, an intracranial ultrasound implant that emits ultrasound to temporarily increase the permeability of the blood-brain barrier.
Discussion / Q&A
Chair: Professor David Walker
14:05 – 14:30 British Summer Time
Closing comments and thanks
Dr Harpreet Hyare
14:30 – 14:35 British Summer Time
Updated: August 2020